Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial

DOI record: { "DOI": "10.1038/s43018-022-00503-w", "ISSN": [ "2662-1347" ], "URL": "http://dx.doi.org/10.1038/s43018-022-00503-w", "abstract": "<jats:title>Abstract</jats:title><jats:p>Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with high morbidity and mortality. Furthermore, impaired humoral response renders severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines less effective and treatment options are scarce. Randomized trials using convalescent plasma are missing for high-risk patients. Here, we performed a randomized, open-label, multicenter trial (<jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE\">https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE</jats:ext-link>) in hospitalized patients with severe COVID-19 (<jats:italic>n</jats:italic> = 134) within four risk groups ((1) cancer (<jats:italic>n</jats:italic> = 56); (2) immunosuppression (<jats:italic>n</jats:italic> = 16); (3) laboratory-based risk factors (<jats:italic>n</jats:italic> = 36); and (4) advanced age (<jats:italic>n</jats:italic> = 26)) randomized to standard of care (control arm) or standard of care plus convalescent/vaccinated anti-SARS-CoV-2 plasma (plasma arm). No serious adverse events were observed related to the plasma treatment. Clinical improvement as the primary outcome was assessed using a seven-point ordinal scale. Secondary outcomes were time to discharge and overall survival. For the four groups combined, those receiving plasma did not improve clinically compared with those in the control arm (hazard ratio (HR) = 1.29; <jats:italic>P</jats:italic> = 0.205). However, patients with cancer experienced a shortened median time to improvement (HR = 2.50; <jats:italic>P</jats:italic> = 0.003) and superior survival with plasma treatment versus the control arm (HR = 0.28; <jats:italic>P</jats:italic> = 0.042). Neutralizing antibody activity increased in the plasma cohort but not in the control cohort of patients with cancer (<jats:italic>P</jats:italic> = 0.001). Taken together, convalescent/vaccinated plasma may improve COVID-19 outcomes in patients with cancer who are unable to intrinsically generate an adequate immune response.</jats:p>", "alternative-id": [ "503" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "16 September 2022" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "29 November 2022" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "29 December 2022" }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 1, "value": "The authors declare no competing interests." } ], "author": [ { "ORCID": "http://orcid.org/0000-0002-7216-7067", "affiliation": [], "authenticated-orcid": false, "family": "Denkinger", "given": "Claudia M.", "sequence": "first" }, { "affiliation": [], "family": "Janssen", "given": "Maike", "sequence": "additional" }, { "affiliation": [], "family": "Schäkel", "given": "Ulrike", "sequence": "additional" }, { "affiliation": [], "family": "Gall", "given": "Julia", "sequence": "additional" }, { "affiliation": [], "family": "Leo", "given": "Albrecht", "sequence": "additional" }, { "affiliation": [], "family": "Stelmach", "given": "Patrick", "sequence": "additional" }, { "affiliation": [], "family": "Weber", "given": "Stefan F.", "sequence": "additional" }, { "affiliation": [], "family": "Krisam", "given": "Johannes", "sequence": "additional" }, { "affiliation": [], "family": "Baumann", "given": "Lukas", "sequence": "additional" }, { "affiliation": [], "family": "Stermann", "given": "Jacek", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-1386-3350", "affiliation": [], "authenticated-orcid": false, "family": "Merle", "given": "Uta", "sequence": "additional" }, { "affiliation": [], "family": "Weigand", "given": "Markus A.", "sequence": "additional" }, { "affiliation": [], "family": "Nusshag", "given": "Christian", "sequence": "additional" }, { "affiliation": [], "family": "Bullinger", "given": "Lars", "sequence": "additional" }, { "affiliation": [], "family": "Schrezenmeier", "given": "Jens-Florian", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-5916-3029", "affiliation": [], "authenticated-orcid": false, "family": "Bornhäuser", "given": "Martin", "sequence": "additional" }, { "affiliation": [], "family": "Alakel", "given": "Nael", "sequence": "additional" }, { "affiliation": [], "family": "Witzke", "given": "Oliver", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-3819-9540", "affiliation": [], "authenticated-orcid": false, "family": "Wolf", "given": "Timo", "sequence": "additional" }, { "affiliation": [], "family": "Vehreschild", "given": "Maria J. G. T.", "sequence": "additional" }, { "affiliation": [], "family": "Schmiedel", "given": "Stefan", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-2836-9224", "affiliation": [], "authenticated-orcid": false, "family": "Addo", "given": "Marylyn M.", "sequence": "additional" }, { "affiliation": [], "family": "Herth", "given": "Felix", "sequence": "additional" }, { "affiliation": [], "family": "Kreuter", "given": "Michael", "sequence": "additional" }, { "affiliation": [], "family": "Tepasse", "given": "Phil-Robin", "sequence": "additional" }, { "affiliation": [], "family": "Hertenstein", "given": "Bernd", "sequence": "additional" }, { "affiliation": [], "family": "Hänel", "given": "Mathias", "sequence": "additional" }, { "affiliation": [], "family": "Morgner", "given": "Anke", "sequence": "additional" }, { "affiliation": [], "family": "Kiehl", "given": "Michael", "sequence": "additional" }, { "affiliation": [], "family": "Hopfer", "given": "Olaf", "sequence": "additional" }, { "affiliation": [], "family": "Wattad", "given": "Mohammad-Amen", "sequence": "additional" }, { "affiliation": [], "family": "Schimanski", "given": "Carl C.", "sequence": "additional" }, { "affiliation": [], "family": "Celik", "given": "Cihan", "sequence": "additional" }, { "affiliation": [], "family": "Pohle", "given": "Thorsten", "sequence": "additional" }, { "affiliation": [], "family": "Ruhe", "given": "Matthias", "sequence": "additional" }, { "affiliation": [], "family": "Kern", "given": "Winfried V.", "sequence": "additional" }, { "affiliation": [], "family": "Schmitt", "given": "Anita", "sequence": "additional" }, { "affiliation": [], "family": "Lorenz", "given": "Hanns-Martin", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-6923-0590", "affiliation": [], "authenticated-orcid": false, "family": "Souto-Carneiro", "given": "Margarida", "sequence": "additional" }, { "affiliation": [], "family": "Gaeddert", "given": "Mary", "sequence": "additional" }, { "affiliation": [], "family": "Halama", "given": "Niels", "sequence": "additional" }, { "affiliation": [], "family": "Meuer", "given": "Stefan", "sequence": "additional" }, { "affiliation": [], "family": "Kräusslich", "given": "Hans-Georg", "sequence": "additional" }, { "affiliation": [], "family": "Müller", "given": "Barbara", "sequence": "additional" }, { "affiliation": [], "family": "Schnitzler", "given": "Paul", "sequence": "additional" }, { "affiliation": [], "family": "Parthé", "given": "Sylvia", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-5601-9307", "affiliation": [], "authenticated-orcid": false, "family": "Bartenschlager", "given": "Ralf", "sequence": "additional" }, { "affiliation": [], "family": "Gronkowski", "given": "Martina", "sequence": "additional" }, { "affiliation": [], "family": "Klemmer", "given": "Jennifer", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-1579-1509", "affiliation": [], "authenticated-orcid": false, "family": "Schmitt", "given": "Michael", "sequence": "additional" }, { "affiliation": [], "family": "Dreger", "given": "Peter", "sequence": "additional" }, { "affiliation": [], "family": "Kriegsmann", "given": "Katharina", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-2215-2059", "affiliation": [], "authenticated-orcid": false, "family": "Schlenk", "given": "Richard F.", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-7166-5232", "affiliation": [], "authenticated-orcid": false, "family": "Müller-Tidow", "given": "Carsten", "sequence": "additional" } ], "container-title": "Nature Cancer", "container-title-short": "Nat Cancer", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2022, 12, 29 ] ], "date-time": "2022-12-29T17:06:50Z", "timestamp": 1672333610000 }, "deposited": { "date-parts": [ [ 2023, 1, 12 ] ], "date-time": "2023-01-12T11:39:00Z", "timestamp": 1673523540000 }, "funder": [ { "name": "The Federal Ministry of Education and Research, Germany" } ], "indexed": { "date-parts": [ [ 2023, 1, 13 ] ], "date-time": "2023-01-13T05:54:39Z", "timestamp": 1673589279324 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2022, 12, 29 ] ] }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 12, 29 ] ], "date-time": "2022-12-29T00:00:00Z", "timestamp": 1672272000000 } }, { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 12, 29 ] ], "date-time": "2022-12-29T00:00:00Z", "timestamp": 1672272000000 } } ], "link": [ { "URL": "https://www.nature.com/articles/s43018-022-00503-w.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s43018-022-00503-w", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s43018-022-00503-w.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1038", "published": { "date-parts": [ [ 2022, 12, 29 ] ] }, "published-online": { "date-parts": [ [ 2022, 12, 29 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1182/blood.2020008824", "author": "A Vijenthira", "doi-asserted-by": "publisher", "first-page": "2881", "journal-title": "Blood", "key": "503_CR1", "unstructured": "Vijenthira, A. et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 136, 2881–2892 (2020).", "volume": "136", "year": "2020" }, { "DOI": "10.1186/s13045-021-01177-0", "author": "L Pagano", "doi-asserted-by": "publisher", "first-page": "168", "journal-title": "J. Hematol. Oncol.", "key": "503_CR2", "unstructured": "Pagano, L. et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J. Hematol. Oncol. 14, 168 (2021).", "volume": "14", "year": "2021" }, { "DOI": "10.1038/s41591-020-0979-0", "author": "EV Robilotti", "doi-asserted-by": "publisher", "first-page": "1218", "journal-title": "Nat. Med.", "key": "503_CR3", "unstructured": "Robilotti, E. V. et al. Determinants of COVID-19 disease severity in patients with cancer. Nat. Med. 26, 1218–1223 (2020).", "volume": "26", "year": "2020" }, { "DOI": "10.1371/journal.pone.0255154", "author": "S Katzenschlager", "doi-asserted-by": "publisher", "first-page": "e0255154", "journal-title": "PLoS ONE", "key": "503_CR4", "unstructured": "Katzenschlager, S. et al. Can we predict the severe course of COVID-19—a systematic review and meta-analysis of indicators of clinical outcome? PLoS ONE 16, e0255154 (2021).", "volume": "16", "year": "2021" }, { "DOI": "10.1007/s10654-020-00698-1", "author": "AT Levin", "doi-asserted-by": "publisher", "first-page": "1123", "journal-title": "Eur. J. Epidemiol.", "key": "503_CR5", "unstructured": "Levin, A. T. et al. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur. J. Epidemiol. 35, 1123–1138 (2020).", "volume": "35", "year": "2020" }, { "DOI": "10.1016/j.jaci.2020.12.620", "author": "AM Shields", "doi-asserted-by": "publisher", "first-page": "870", "journal-title": "J. Allergy Clin. Immunol.", "key": "503_CR6", "unstructured": "Shields, A. M., Burns, S. O., Savic, S. & Richter, A. G. COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. J. Allergy Clin. Immunol. 147, 870–875.e1 (2021).", "volume": "147", "year": "2021" }, { "DOI": "10.1097/TP.0000000000003523", "author": "Y Azzi", "doi-asserted-by": "publisher", "first-page": "37", "journal-title": "Transplantation", "key": "503_CR7", "unstructured": "Azzi, Y., Bartash, R., Scalea, J., Loarte-Campos, P. & Akalin, E. COVID-19 and solid organ transplantation: a review article. Transplantation 105, 37–55 (2021).", "volume": "105", "year": "2021" }, { "DOI": "10.1016/S2665-9913(21)00059-X", "author": "J Avouac", "doi-asserted-by": "publisher", "first-page": "e419", "journal-title": "Lancet Rheumatol.", "key": "503_CR8", "unstructured": "Avouac, J. et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 3, e419–e426 (2021).", "volume": "3", "year": "2021" }, { "DOI": "10.1158/2159-8290.CD-21-0191", "author": "T Bilich", "doi-asserted-by": "publisher", "first-page": "1982", "journal-title": "Cancer Discov.", "key": "503_CR9", "unstructured": "Bilich, T. et al. Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in patients with cancer. Cancer Discov. 11, 1982–1995 (2021).", "volume": "11", "year": "2021" }, { "DOI": "10.1038/s41408-021-00534-z", "author": "F Malard", "doi-asserted-by": "publisher", "journal-title": "Blood Cancer J", "key": "503_CR10", "unstructured": "Malard, F. et al. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J. 11, 142 (2021).", "volume": "11", "year": "2021" }, { "DOI": "10.1056/NEJMoa2114583", "author": "EG Levin", "doi-asserted-by": "publisher", "first-page": "e84", "journal-title": "N. Engl. J. Med.", "key": "503_CR11", "unstructured": "Levin, E. G. et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).", "volume": "385", "year": "2021" }, { "DOI": "10.1093/cid/ciaa478", "doi-asserted-by": "publisher", "key": "503_CR12", "unstructured": "Bhimraj, A. et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa478 (2020)." }, { "DOI": "10.1016/j.cell.2021.05.005", "author": "D Corti", "doi-asserted-by": "publisher", "first-page": "3086", "journal-title": "Cell", "key": "503_CR13", "unstructured": "Corti, D., Purcell, L. A., Snell, G. & Veesler, D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 184, 3086–3108 (2021).", "volume": "184", "year": "2021" }, { "DOI": "10.1002/hon.2974", "author": "B Weinbergerová", "doi-asserted-by": "publisher", "first-page": "280", "journal-title": "Hematol. Oncol.", "key": "503_CR14", "unstructured": "Weinbergerová, B.Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients—a Czech multicenter experience. Hematol. Oncol. 40, 280–286 (2022).", "volume": "40", "year": "2022" }, { "DOI": "10.1080/08923973.2021.1993894", "author": "CS Kow", "doi-asserted-by": "publisher", "first-page": "28", "journal-title": "Immunopharmacol. Immunotoxicol.", "key": "503_CR15", "unstructured": "Kow, C. S., Ramachandram, D. S. & Hasan, S. S. The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Immunopharmacol. Immunotoxicol. 44, 28–34 (2022).", "volume": "44", "year": "2022" }, { "DOI": "10.1371/journal.pone.0270196", "author": "S Saha", "doi-asserted-by": "publisher", "first-page": "e0270196", "journal-title": "PLoS ONE", "key": "503_CR16", "unstructured": "Saha, S. Death and invasive mechanical ventilation risk in hospitalized COVID-19 patients treated with anti-SARS-CoV-2 monoclonal antibodies and/or antiviral agents: a systematic review and network meta-analysis protocol. PLoS ONE 17, e0270196 (2022).", "volume": "17", "year": "2022" }, { "DOI": "10.1016/S0140-6736(21)00897-7", "author": "RECOVERY Collaborative Group", "doi-asserted-by": "publisher", "first-page": "2049", "journal-title": "Lancet", "key": "503_CR17", "unstructured": "RECOVERY Collaborative Group Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 397, 2049–2059 (2021).", "volume": "397", "year": "2021" }, { "DOI": "10.1056/NEJMoa2033700", "author": "R Libster", "doi-asserted-by": "publisher", "first-page": "610", "journal-title": "N. Engl. J. Med.", "key": "503_CR18", "unstructured": "Libster, R. et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N. Engl. J. Med. 384, 610–618 (2021).", "volume": "384", "year": "2021" }, { "author": "V Piechotta", "first-page": "CD013600", "journal-title": "Cochrane Database Syst. Rev.", "key": "503_CR19", "unstructured": "Piechotta, V. et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review. Cochrane Database Syst. Rev. 7, CD013600 (2021).", "volume": "7", "year": "2021" }, { "DOI": "10.1056/NEJMoa2031304", "author": "VA Simonovich", "doi-asserted-by": "publisher", "first-page": "619", "journal-title": "N. Engl. J. Med.", "key": "503_CR20", "unstructured": "Simonovich, V. A. et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N. Engl. J. Med. 384, 619–629 (2020).", "volume": "384", "year": "2020" }, { "DOI": "10.1001/jama.2020.10044", "author": "L Li", "doi-asserted-by": "publisher", "first-page": "460", "journal-title": "J. Am. Med. Assoc.", "key": "503_CR21", "unstructured": "Li, L. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. J. Am. Med. Assoc. 324, 460–470 (2020).", "volume": "324", "year": "2020" }, { "DOI": "10.1136/bmjopen-2021-055189", "author": "M Bajpai", "doi-asserted-by": "publisher", "first-page": "e055189", "journal-title": "BMJ Open", "key": "503_CR22", "unstructured": "Bajpai, M. et al. Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial). BMJ Open 12, e055189 (2022).", "volume": "12", "year": "2022" }, { "DOI": "10.1172/JCI150646", "author": "MR O’Donnell", "doi-asserted-by": "publisher", "first-page": "e150646", "journal-title": "J. Clin. Invest.", "key": "503_CR23", "unstructured": "O’Donnell, M. R. et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J. Clin. Invest. 131, e150646 (2021).", "volume": "131", "year": "2021" }, { "DOI": "10.1038/s41591-021-01488-2", "author": "P Bégin", "doi-asserted-by": "publisher", "first-page": "2012", "journal-title": "Nat. Med.", "key": "503_CR24", "unstructured": "Bégin, P. et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat. Med. 27, 2012–2024 (2021).", "volume": "27", "year": "2021" }, { "DOI": "10.1016/j.ijid.2021.06.034", "author": "FW Hamilton", "doi-asserted-by": "publisher", "first-page": "114", "journal-title": "Int. J. Infect. Dis.", "key": "503_CR25", "unstructured": "Hamilton, F. W., Lee, T., Arnold, D. T., Lilford, R. & Hemming, K. Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial. Int. J. Infect. Dis. 109, 114–117 (2021).", "volume": "109", "year": "2021" }, { "DOI": "10.1001/jama.2021.18178", "author": "Writing Committee for the REMAP-CAP Investigators", "doi-asserted-by": "publisher", "first-page": "1690", "journal-title": "J. Am. Med. Assoc.", "key": "503_CR26", "unstructured": "Writing Committee for the REMAP-CAP Investigators Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. J. Am. Med. Assoc. 326, 1690–1702 (2021).", "volume": "326", "year": "2021" }, { "DOI": "10.1038/s41375-022-01511-6", "author": "T Hueso", "doi-asserted-by": "publisher", "first-page": "1025", "journal-title": "Leukemia", "key": "503_CR27", "unstructured": "Hueso, T. et al. Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. Leukemia 36, 1025–1034 (2022).", "volume": "36", "year": "2022" }, { "DOI": "10.1001/jamaoncol.2021.1799", "author": "MA Thompson", "doi-asserted-by": "publisher", "first-page": "1167", "journal-title": "JAMA Oncol.", "key": "503_CR28", "unstructured": "Thompson, M. A. et al. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol. 7, 1167–1175 (2021).", "volume": "7", "year": "2021" }, { "DOI": "10.1056/NEJMoa2019014", "author": "AB Cavalcanti", "doi-asserted-by": "publisher", "first-page": "2041", "journal-title": "N. Engl. J. Med.", "key": "503_CR29", "unstructured": "Cavalcanti, A. B. et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19. N. Engl. J. Med. 383, 2041–2052 (2020).", "volume": "383", "year": "2020" }, { "DOI": "10.1056/NEJMoa2028700", "author": "IO Rosas", "doi-asserted-by": "publisher", "first-page": "1503", "journal-title": "N. Engl. J. Med.", "key": "503_CR30", "unstructured": "Rosas, I. O. et al. Tocilizumab in hospitalized patients with severe COVID-19 pneumonia. N. Engl. J. Med. 384, 1503–1516 (2021).", "volume": "384", "year": "2021" }, { "DOI": "10.1186/s13063-020-04735-y", "author": "M Janssen", "doi-asserted-by": "publisher", "journal-title": "Trials", "key": "503_CR31", "unstructured": "Janssen, M. et al. A randomized open label phase-II clinical trial with or without infusion of plasma from subjects after convalescence of SARS-CoV-2 infection in high-risk patients with confirmed severe SARS-CoV-2 disease (RECOVER): a structured summary of a study protocol for a randomised controlled trial. Trials 21, 828 (2020).", "volume": "21", "year": "2020" }, { "DOI": "10.1056/NEJMoa2119657", "author": "DJ Sullivan", "doi-asserted-by": "publisher", "first-page": "1700", "journal-title": "N. Engl. J. Med.", "key": "503_CR32", "unstructured": "Sullivan, D. J. et al. Early outpatient treatment for COVID-19 with convalescent plasma. N. Engl. J. Med. 386, 1700–1711 (2022).", "volume": "386", "year": "2022" }, { "DOI": "10.1038/s41591-021-01678-y", "author": "LA VanBlargan", "doi-asserted-by": "publisher", "first-page": "490", "journal-title": "Nat. Med.", "key": "503_CR33", "unstructured": "VanBlargan, L. A. et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. 28, 490–495 (2022).", "volume": "28", "year": "2022" }, { "DOI": "10.1038/s41598-022-06629-2", "author": "Y Yu", "doi-asserted-by": "publisher", "journal-title": "Sci. Rep.", "key": "503_CR34", "unstructured": "Yu, Y. et al. mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. Sci. Rep. 12, 2628 (2022).", "volume": "12", "year": "2022" }, { "DOI": "10.1016/j.isci.2021.102898", "author": "P De Candia", "doi-asserted-by": "publisher", "first-page": "102898", "journal-title": "iScience", "key": "503_CR35", "unstructured": "De Candia, P. et al. Effect of time and titer in convalescent plasma therapy for COVID-19. iScience 24, 102898 (2021).", "volume": "24", "year": "2021" }, { "DOI": "10.1056/NEJMoa2001282", "author": "B Cao", "doi-asserted-by": "publisher", "first-page": "1787", "journal-title": "N. Engl. J. Med.", "key": "503_CR36", "unstructured": "Cao, B. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N. Engl. J. Med. 382, 1787–1799 (2020).", "volume": "382", "year": "2020" }, { "DOI": "10.1111/ajt.17054", "author": "L Benning", "doi-asserted-by": "publisher", "first-page": "1873", "journal-title": "Am. J. Transplant.", "key": "503_CR37", "unstructured": "Benning, L. et al. Neutralizing antibody response against the B.1.617.2 (Delta) and the B.1.1.529 (Omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. Am. J. Transplant. 22, 1873–1883 (2022).", "volume": "22", "year": "2022" } ], "reference-count": 37, "references-count": 37, "relation": {}, "resource": { "primary": { "URL": "https://www.nature.com/articles/s43018-022-00503-w" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Cancer Research", "Oncology" ], "subtitle": [], "title": "Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy" }